Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Extra income should be directed toward goals you care about: emergency fund, debt repayment, or investments, while maintaining everyday needs.
13,631 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
A sharp intraday drop in Micron shares sparked by AI memory demand concerns set off a broader discussion about pricin...
When two tech giants sit in the same valuation neighborhood, smart investors focus on the details. This guide breaks ...
Texas Instruments preps for July earnings with a guidance-led breakout in industrial and data-center demand, plus a f...
Jamie Dimon argues that AI will reshape work but cautions against panic, highlighting retraining and internal job red...
Sandisk recently surged after spinning out from Western Digital, trading well above its 52-week low. This deep dive w...
Memory chips power today’s data centers, AI accelerators, and personal devices. This guide breaks down the case for S...
Wall Street just wrapped a scorching quarter, leaving many investors dazzled by gains and wary of the risk. This guid...
As Berkshire transitions to Greg Abel, Warren Buffett’s final investment points to a return to era-defining brands. T...
Rivian has faced volatility, with a notable pullback this year. This guide breaks down what’s driving the moves, what...
Toll Brothers posted a strong first quarter, underscoring resilience in the luxury segment through disciplined execut...
Vistra surged dramatically, but does the rally leave room for gains or is the stock now a trap for late buyers? This ...